Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Central and Peripheral Actions of Alpha 2 -Adrenergic Agonists on Renal Function in Long-Evans and Brattleboro Rats

View through CrossRef
The effects of 3 α<sub>2</sub>-adrenergic receptor agonists on renal function in vasopressin (AVP)-deficient Brattleboro (DI) rats were evaluated. The aim of this study was to determine the relative contribution of central versus peripheral α<sub>2</sub>- adrenoceptors in mediating diuresis and natriuresis, as well as the role of α<sub>2</sub>-adrenoceptors in antagonizing the actions of AVP. In addition to the studies of renal function, the effects of AVP deficiency on renal α<sub>2</sub>-adrenoceptor affinity and number was evalauted along with determination of peripheral catecholamine stores. The centrally acting α<sub>2</sub>-adrenergic agonists guanabenz and guanfacine significantly increased urine output and sodium excretion in Long-Evans (LE) rats. Guanabenz and guanfacine increased urine output in DI rats but failed to increase sodium excretion. The polar α<sub>2</sub>-adrenergic agonist, ST-91, increased sodium excretion in both LE and DI rats, however, at a dose of 1.0 mg/kg urine output was significantly decreased in DI rats. The 3 α<sub>2</sub>-adrenergic agonists increased potassium excretion in LE rats, but at the 1.0-mg/kg dose of guanabenz and ST-91, potassium excretion was significantly inhibited in DI rats. Renal α<sub>2</sub>-adrenergic receptors and norepinephrine stores were not altered in DI rats. Adrenal NE stores were significantly elevated in DI rats relative to LE rats. The results of this study suggest that in the absence of AVP, centrally acting α<sub>2</sub>-adrenergic agonists have limited natriuretic action, although peripheral activation of α<sub>2</sub>-adrenoceptors is sufficient to elicit natriuresis irrespective of the presence of AVP. The chronic deficiency of AVP does not alter renal α<sub>2</sub>-adrenergic receptor number, but the natriuretic and kaliuretic actions of α<sub>2</sub>-adrenergic agonists are altered in DI rats.
Title: Central and Peripheral Actions of Alpha 2 -Adrenergic Agonists on Renal Function in Long-Evans and Brattleboro Rats
Description:
The effects of 3 α<sub>2</sub>-adrenergic receptor agonists on renal function in vasopressin (AVP)-deficient Brattleboro (DI) rats were evaluated.
The aim of this study was to determine the relative contribution of central versus peripheral α<sub>2</sub>- adrenoceptors in mediating diuresis and natriuresis, as well as the role of α<sub>2</sub>-adrenoceptors in antagonizing the actions of AVP.
In addition to the studies of renal function, the effects of AVP deficiency on renal α<sub>2</sub>-adrenoceptor affinity and number was evalauted along with determination of peripheral catecholamine stores.
The centrally acting α<sub>2</sub>-adrenergic agonists guanabenz and guanfacine significantly increased urine output and sodium excretion in Long-Evans (LE) rats.
Guanabenz and guanfacine increased urine output in DI rats but failed to increase sodium excretion.
The polar α<sub>2</sub>-adrenergic agonist, ST-91, increased sodium excretion in both LE and DI rats, however, at a dose of 1.
0 mg/kg urine output was significantly decreased in DI rats.
The 3 α<sub>2</sub>-adrenergic agonists increased potassium excretion in LE rats, but at the 1.
0-mg/kg dose of guanabenz and ST-91, potassium excretion was significantly inhibited in DI rats.
Renal α<sub>2</sub>-adrenergic receptors and norepinephrine stores were not altered in DI rats.
Adrenal NE stores were significantly elevated in DI rats relative to LE rats.
The results of this study suggest that in the absence of AVP, centrally acting α<sub>2</sub>-adrenergic agonists have limited natriuretic action, although peripheral activation of α<sub>2</sub>-adrenoceptors is sufficient to elicit natriuresis irrespective of the presence of AVP.
The chronic deficiency of AVP does not alter renal α<sub>2</sub>-adrenergic receptor number, but the natriuretic and kaliuretic actions of α<sub>2</sub>-adrenergic agonists are altered in DI rats.

Related Results

North Syrian Mortaria and Other Late Roman Personal and Utility Objects Bearing Inscriptions of Good Luck
North Syrian Mortaria and Other Late Roman Personal and Utility Objects Bearing Inscriptions of Good Luck
<span style="font-size: 11pt; color: black; font-family: 'Times New Roman','serif'">&Pi;&Eta;&Lambda;&Iota;&Nu;&Alpha; &Iota;&Gamma;&Delta...
Un manoscritto equivocato del copista santo Theophilos († 1548)
Un manoscritto equivocato del copista santo Theophilos († 1548)
<p><font size="3"><span class="A1"><span style="font-family: 'Times New Roman','serif'">&Epsilon;&Nu;&Alpha; &Lambda;&Alpha;&Nu;&...
Adrenergic and Cholinergic Regulation of in vitro Melatonin Release during Ontogeny in the Pineal Gland of Long Evans Rats
Adrenergic and Cholinergic Regulation of in vitro Melatonin Release during Ontogeny in the Pineal Gland of Long Evans Rats
Melatonin, produced by the pineal gland, plays an important role in a great variety of neuroendocrine functions. The rhythmic release of melatonin by the mammalian pineal gland is ...
PROCEEDINGS OF THE AUSTRALASIAN SOCIETY OF CLINICAL AND EXPERIMENTAL PHARMACOLOGISTS
PROCEEDINGS OF THE AUSTRALASIAN SOCIETY OF CLINICAL AND EXPERIMENTAL PHARMACOLOGISTS
1.Effect of chronic haloperidol treatment on D‐2 receptors labelled by (3H)‐spiperone in homogenates of rat corpus striatum. A. L. Gundlach, D. J. de Vries and P. M. Beart2.The eff...
The Molecular Basis of Alpha-Thalassemia in the Qatari Pediatric Population
The Molecular Basis of Alpha-Thalassemia in the Qatari Pediatric Population
BackgroundAnemia is the most common hematologic abnormality that a pediatrician encounters in clinical practice. Alpha-Thalassemia (a-thal) is widely reported in the Arabian Penins...
Adrenergic Regulation of Vascular Smooth Muscle
Adrenergic Regulation of Vascular Smooth Muscle
Abstract The sections in this article are: Morphology of Adrenergic Innervation ...
Beta-adrenergic blocker treatment for COVID-19
Beta-adrenergic blocker treatment for COVID-19
More than 2.5 million people were affected by COVID-19 and it had caused around 175000 deaths as of April 23, 2020. Currently no effective treatment option is present for COVID-19 ...
PROCEEDINGS OF THE AUSTRALASIAN SOCIETY OF CLINICAL AND EXPERIMENTAL PHARMACOLOGISTS
PROCEEDINGS OF THE AUSTRALASIAN SOCIETY OF CLINICAL AND EXPERIMENTAL PHARMACOLOGISTS
14th Annual Meeting, December 1980, Canberra1. Effect of dexamethasone on pineal β‐adrenoceptors. C. A. Maxwell, A. Foldes, N. T. Hinks and R. M. Hoskinson2. A clinicopathological ...

Back to Top